Kenneth Stubbs
Internal Medicine · Natchez, MSNPI 1659312585
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 517 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,424 and has fallen 99.3% since, to $17 in 2025. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Boehringer Ingelheim$685
- AbbVie$681
- Johnson & Johnson$658
- Novo Nordisk$551
- Merck$547
- plus $4K from 23 others
What the payments were for
- Food & beverage$7,90099%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 66 | $1,004 |
| Boehringer Ingelheim | 40 | $685 |
| AbbVie(2 entities) | 51 | $681 |
| Johnson & Johnson | 42 | $658 |
| Novo Nordisk | 32 | $551 |
| Merck | 39 | $547 |
| Lilly USA, LLC | 34 | $510 |
| AstraZeneca | 33 | $497 |
| Astellas Pharma US Inc | 26 | $469 |
| Amgen | 27 | $450 |
| Novartis | 32 | $448 |
| Sanofi-aventis U.S. LLC | 24 | $406 |
| GSK | 24 | $332 |
| Teva Pharmaceuticals USA, Inc. | 7 | $128 |
| Abbott | 7 | $122 |
| Avanir Pharmaceuticals, Inc. | 7 | $93 |
| Amarin Pharma, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Dexcom, Inc. | 3 | $44 |
| Biocryst US Sales Co., LLC | 2 | $42 |
| Biogen | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Abiomed | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
$8,000 in reported general payments places this provider in the 95th percentile of 846 internal medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $53,916 |
| OzempicSemaglutide | 25 | $41,215 |
| JardianceEmpagliflozin | 36 | $40,035 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,683 |
| MyrbetriqMirabegron | 13 | $10,221 |
| FarxigaDapagliflozin Propanediol | 13 | $9,585 |
| TradjentaLinagliptin | 11 | $6,038 |
| Rosuvastatin Calcium | 187 | $3,108 |
| Valsartan | 81 | $1,632 |
| Estradiol (Twice Weekly)Estradiol | 22 | $1,346 |
| Ezetimibe | 58 | $1,218 |
| Levothyroxine Sodium | 80 | $1,008 |
| Potassium Chloride | 28 | $818 |
| Pantoprazole Sodium | 59 | $774 |
| Allopurinol | 65 | $770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,004 | $53,91671 claims |
| Boehringer IngelheimJardiance, Tradjenta | $685 | $46,07247 claims |
| Novo NordiskOzempic | $551 | $41,21525 claims |
| GSKTrelegy Ellipta | $332 | $14,68319 claims |
| Astellas Pharma US IncMyrbetriq | $469 | $10,22113 claims |
| AstraZenecaFarxiga | $497 | $9,58513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Natchez
- Edward DalyNatchez$11K
- Blane MireNatchez$8K
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- Jeffrey DennisOxford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.